Methods for constructing antibiotic resistance free vaccines
View Patent ↗The present invention provides Listeria vaccine strains that express a heterologous antigen and a metabolic enzyme, and methods of generating same.
1. A recombinant Listeria monocytogenes strain, comprising a mutation in a D-alanine racemase gene and in a D-amino acid transferase gene in said Listeria strain's chromosome, said Listeria strain further comprising a plasmid comprising: a) a first nucleic acid sequence encoding a polypeptide, wherein said polypeptide comprises a heterologous antigen, and b) a second nucleic acid sequence encoding a metabolic enzyme, wherein said metabolic enzyme complements the mutation in said recombinant Listeria strain's chromosome, wherein said metabolic enzyme encoded by said second nucleic acid is a D-alanine racemase enzyme, wherein said polypeptide is a fusion protein comprising said heterologous antigen and a non-hemolytic fragment of a listeriolysin (LLO) protein, wherein the chromosome of said recombinant Listeria strain further lacks a prfA gene, wherein said first and said second nucleic acids are operably linked to a promoter/regulatory sequence, wherein said promoter/regulatory sequence linked to said second nucleic acid sequence comprises a truncated p60 promoter region, wherein said plasmid comprises a gram positive and a gram negative origin of replication region, and wherein said plasmid does not confer antibiotic resistance upon said recombinant Listeria strain.
2. The recombinant Listeria strain of claim 1 , wherein said gram positive origin of replication is a Listeria monocytogenes gram-positive origin of replication and wherein said gram negative origin of replication is an E. coli origin of replication.
3. The recombinant Listeria strain of claim 1 , wherein said mutation is a deletion in said D-alanine racemase gene and in said D-amino acid transferase gene in said Listeria strain's chromosome.
4. The recombinant Listeria strain of claim 1 , wherein said prfA gene is present on said plasmid.
5. The recombinant Listeria of claim 1 , wherein said heterologous antigen is a human papilloma virus E7 antigen (HPV-E7).
6. The recombinant Listeria of claim 1 , wherein said promoter/regulatory sequence linked to said first nucleic acid is a hly promoter.
7. A method of producing a recombinant Listeria strain, said method comprising the steps of: (a) introducing a mutation in a D-alanine racemase gene and in a D-amino acid transferase gene in said Listeria strain's chromosome, (b) transforming said Listeria strain with a plasmid comprising: i) a first nucleic acid sequence encoding a polypeptide, wherein said polypeptide comprises a heterologous antigen, ii) a second nucleic acid sequence encoding a metabolic enzyme, wherein said metabolic enzyme complements the mutation in said recombinant Listeria strain's chromosome, wherein said metabolic enzyme encoded by said second nucleic acid is a D-alanine racemase enzyme, wherein said polypeptide is a fusion protein comprising said heterologous antigen and a non-hemolytic fragment of a listeriolysin (LLO) protein, wherein the chromosome of said recombinant Listeria strain further lacks a prfA gene, wherein said first and said second nucleic acids are operably linked to a promoter/regulatory sequence, wherein said promoter/regulatory sequence linked to said second nucleic acid sequence comprises a truncated p60 promoter region, wherein said plasmid comprises a gram positive and a gram negative origin of replication region, and wherein said plasmid does not confer antibiotic resistance upon said recombinant Listeria strain, thereby producing a recombinant Listeria strain comprising a mutation in a D-alanine racemase gene and in a D-amino acid transferase gene in said Listeria 's chromosome.
8. The method of claim 7 , wherein said gram negative origin of replication is an E. coli origin of replication, thereby enabling stable maintenance of said plasmid is an E. coli strain.
9. The method of claim 7 , whereby the step of transforming utilizes a prophage integration site of said Listeria strain.
10. The method of claim 7 , wherein said heterologous antigen is a human papilloma virus E7 antigen (HPV-E7).
11. The method of claim 7 , wherein said promoter/regulatory sequence linked to said first nucleic acid is a hly promoter.
12. The method of claim 7 , wherein said prfA gene is present on said plasmid.